IJDVL Home  
 

STUDIES
[View FULLTEXT] [Download PDF]  
Year : 2003  |  Volume : 69  |  Issue : 5  |  Page : 334-337

Treatment of pemphigus with intravenous pulse cyclophosphamide

NR Gokhale, PM Mahajan, RR Sule, VA Belgaumkar, SM Jain 
 Department of Dermatology, Venereology and Leprosy, B. J. Medical College and Sassoon General Hospitals, Pune - 411001, India

Correspondence Address:
N R Gokhale
39/30, Smruti Lane No. 9, Prabhat Road, Pune - 411004
India

Background: The complications associated with the use of systemic corticosteroid therapy have prompted a search for alternative agents. However, these agents are themselves associated with increased risk of myelosuppression or malignancy. Methods: The present study included twenty patients with recalcitrant pemphigus or steroid induced side effects who were treated with intravenous cyclophosphamide pulse therapy. Results: Out of 18 patients who completed the study, 14 showed good to excellent response. Thirteen were able to decrease their daily dose of steroid to 5-10 mg prednisolone while one could stop steroids altogether. Most patients did not experience serious side effects. Discussion: Thus intravenous pulse cyclophosphamide is a promising form of therapy in pemphigus either recalcitrant or intolerant to steroid therapy. The decreased total cumulative dose of cyclophosphamide with intravenous therapy as compared to oral therapy may reduce the incidence of secondary malignancy.


How to cite this article:
Gokhale N R, Mahajan P M, Sule R R, Belgaumkar V A, Jain S M. Treatment of pemphigus with intravenous pulse cyclophosphamide.Indian J Dermatol Venereol Leprol 2003;69:334-337


How to cite this URL:
Gokhale N R, Mahajan P M, Sule R R, Belgaumkar V A, Jain S M. Treatment of pemphigus with intravenous pulse cyclophosphamide. Indian J Dermatol Venereol Leprol [serial online] 2003 [cited 2020 Feb 29 ];69:334-337
Available from: http://www.ijdvl.com/article.asp?issn=0378-6323;year=2003;volume=69;issue=5;spage=334;epage=337;aulast=Gokhale;type=0


 

Saturday, February 29, 2020
 Site Map | Home | Contact Us | Feedback | Copyright and disclaimer